Labcorp's ColoSense becomes ACS preferred screening
The stool-based RNA test is recommended for average-risk adults 45+ to improve early detection.
See the latest news and media coverage for Labcorp. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical laboratory and drug development services provider
labcorp.comLast updated
In short: Labcorp grew its 2026 financial outlook following strong Q1 results while expanding its diagnostic reach through new AI platforms and partnerships.
The stool-based RNA test is recommended for average-risk adults 45+ to improve early detection.
The report highlights progress in sustainability, access to care, employee well-being, sustainable operations, and community impact. It includes workforce investments, EcoVadis ratings, and charitable grants.
The FDA-cleared test detects norfentanyl with over 96% accuracy in 10 minutes, aiding quick clinical decisions amid rising overdose deaths.
Revenue grew 5.8% to $3.54 billion. Adjusted EPS increased 10.6% to $4.25. Strategic collaborations advanced in diagnostics and AI.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining ...
According to the complaint, which was filed last week in the Circuit Court of Cook County, Illinois County Department, Chancery Division, following its acquisition...
Laboratory services company Labcorp has agreed to a $35 million settlement in a class-action lawsuit stemming from its third-party debt-collection vendor. From August 2018 to...
Labcorp Holdings stock snapshot Labcorp Holdings (LH) stock has been moving without a clear single...
Track Labcorp and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Labcorp and other trending companies.